Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're full of crap. Go troll another board. Even if Nemus doubled the issued shares they'd be way lower than CBNX, OWCP, IMLFF and all the others. Why don't you do yourself a favor and read a real press release where Nemus specifies how their MRSA drug tested recently instead of all the fluff the orthers put out?
That's a notice that previously issued shares are eligible for re-sale on the public market. They have the lowest issued shares of any public cannabinoid company.
This is the kind of thing I'm talking about. What does this press release mean? They've been talking about developing the same 2 drugs for 3 years so how is this press release any different than previous ones? I'd like to see specifics on what advancements they've made since the last release. This adds nothing to their progress and where do the pending patents stand that they filed 2 years ago?
Whatever works. I'm happy I got in and that this thing is climbing. I just don't really know if what they have is actually valuable. Others are betting they do so I'll go along for the ride and dump it if I don't see secured patents soon or validation of their Bioinformatics and biosynthesis are worthwhile compared to what else is already out there.
Nemus has done a good job of keeping dilution to a minimum. InMed has 4x times the outstanding shares yet their stock price is double Nemus'. Dilution hasn't hurt them. I think Nemus has the lowest amount of outstanding shares in the sector so they've left plenty of room to issue more for funding.
Nemus has multiple patents and I believe better IP than all cannabinoid companies. The University has been studying and getting patents for 40 years so how could it not?
I'm not convinced InMed has anything special with their biosynthesis. Nobody in this sector has gone to them and everyone is using effective forms of biosynthesis who are making synthetic drugs. Nemus is probably 2 years ahead of InMed in drug development. If you compare their press releases to all the others in the sector, Nemus' are very scientifically detailed. No fluff and nothing to pump the stock. InMed has no patents and their claims are loaded with insinuations that pump it up.
I think Nemus is currently negotiating partnership deal(s) and wouldn't be surprised if they announce something shortly. If not right now, they'll raise another $1 million until they do secure a deal.
Yes Ingram has his pick of anything and chose Nemus and put in $250k. He's very involved. Lykos walked away from some huge paydays on several boards to devote full time to this.
I think Murphy took over as CEO to cut unnecessary costs. He's a brilliant man and they think he is more than capable to handle 2 roles with the others who know how to run a company.
I own both and to say it's a no brainer is just pumping. Nemus has a 1/4 of the outstanding shares and is much further along with their drug candidates and they have much more in their pipeline. If InMed has more value then it's solely based on their biosynthesis and bioinformatics. But we have no idea if either of those are better than what the competition is doing and despite the PR releases, there is competition. InMed is purely speculative at this point.
So private companies already using non-chemical biosynthesis to manufacture cannabinoids aren't competition?
According to their management analysis filed on 2/27, they share an office. It also indicates they have no patents yet and that their patents are pending. I'm very happy this went up today but I still haven't figured out what they have. Biosynthesis is already being done and other companies have patents and have proven they can make their drugs so they're 2 years ahead. But whatever, I'll ride it out and see where this goes.
This has nothing to do with their drugs. They are years away from trials. Something else is at play here. Maybe it's the biosynthesis or the bioinformatics. Sometimes we never know with these penny stocks.
I have no idea who has a better process but I bought shares knowing they already have major competition and that their PR was somewhat misleading because Teewinot and others are already doing what InMed claims they can do. I don't think they have anything unique but I'm hoping it's good enough to have good market share. They are also 2-3 years away from clinical trials on their leading candidates and certainly behind others on their glaucoma candidate. So to say this is a $1 billion company with nobody doing what they're doing and they're the leader just isn't true in my opinion. However, I think there is enough there to take a shot with them and I have. I own 3 cannabinoid stocks now and looking for a couple others that could hit to have coverage. I own this, Zynerba and Nemus. I wouldn't touch GW at its current price and don't think they have great candidates. Sativex was a disaster. Oral sprays don't work with cannabinoids and it has way too much alcohol in it so it will spray.
From my research, here are my opinions of the 3:
Zynerba-well funded and great CEO and is most likely to succeed because of that. IP is pretty good. Current price seems reasonable and should pop with results. Their patch can be used for multiple purposes if approved. Market cap $250 million
Nemus-has the best IP of all cannabinoid companies. They already know their glaucoma and Staph drugs work which are worth a lot. Their chemo side effect drug could get fast track approval in 2 years. Problem is they're very low key and seem to be working on deals quietly behind the scenes. Good CEO and Doug Ingram (Allergan-President) is very involved so there must be something there. If they get a partnership deal which I think is coming, this stock has the most price upside because they have the lowest market cap of any cannabinoid company by far. Their pipeline has the most potential value but their stock price just doesn't move much which is frustrating. Market cap $7 million.
InMed-probably the best Canadian cannabinoid company which gives them some advantages. Not sure about their IP but if it's legit, they'll do well and it's worth the risk. I also like how their price seems to go up and maintains traction and how they've been able to raise money even though they seem to be behind. Management is doing something right. Market cap $45 million.
Thank you. I've read this before but the question for me and should be for everyone is their biosynthesis process better than what other companies are using? Teewinot makes a similar claim and they are already developing cannabinoids for other companies.
I own shares and I hope you're right. One company has come to InMed that's been made public. You literally have no idea if their biosynthesis process is cheaper or more efficient than others out there already. Some are using yeast and not e-coli. Which one is better?
Is the cream synthetic or made from the plant?
A few weeks ago, the same identical article appeared on various market news websites which I've only seen with pumps. Maybe they didn't. The Forbes article was most likely not and it seems to have driven the price up.
As far as being schooled, I've asked questions and nobody answered so maybe you can. I did buy shares to take a shot but I always like to cut through the bs and the message board pumping to get an idea if people see the same things I see or have more knowledge and information. I believe some of the companies claims are a bit of a reach so here are my questions if you care to answer:
-they claim an e-coli biosynthesis process unlike any others that everyone in the sector will want because most cannabinoid drug companies use the plant. However, GW is the only one I'm aware of that is using the plant and others aren't using chemical biosynthesis. What makes InMed's technology better and more valuable than those using Teewinot's for example?
-what they call Bioinformatics has been around in pharma for quite a while. What makes them think nobody is doing the same thing in cannabinoids?
-their 2 leading drug candidates do not have patent approvals yet and they still have to make the drugs and establish that they have a 2 year shelf life. Protocol is that a 2 year shelf life can be proven in 6 months. I estimate that will take at least 2 years before they can start trials. That's assuming the patents are approved and they can make the drug. How long does anyone else think it will take and will they attempt to make the drug without patent approval?
They did a pump campaign a few weeks ago. The unknown is the value of their Bioinformatics and biosynthesis process because they're way behind others as far as moving their drugs to trials. Not sure about their biosynthesis because others are doing it without chemicals.
Unless there's a huge policy shift in the US, synthetic drugs will be the only drugs that get approved by the FDA. There should be a place for both as some drugs need to go through the process to make sure there are no impurities. But unless there is a shift, when synthetic drugs start getting approval, they will end up dominating the market because they will be cheaper, covered by insurance and prescribed by doctors for liability reasons and because they're indoctrinated that only FDA approved drugs are safe.
They should start paying for pumps like InMed and others. It's working for them with no news and no confirmed patents or having made any of their drugs yet.
You guys just don't get it. It doesn't matter if they have a relationship. The cream is an unapproved drug. If they sell it in the US it would be Federally illegal. GW has a drug called called Sativex that went though trials all while they had their relationship with the FDA. It was not approved. GW could have done 2 things, they could have sold Sativex in the legal states before it was denied and it could sell it now. Zynerba has a topical cream they're developing under FDA protocol as well. Why do you think GW and Zynerba aren't selling it in the legal US states now? Why wouldn't they want that revenue if it's such a non-issue? Zynerba could sell theirs as a cream right now in the legal states. Why are they waiting for FDA approval? Nemus has a topical cream for Staph infections that they could easily put on the market now and call it a cosmetic. Why are they all waiting?
If OWCP has worked out some type of agreement with the FDA that they can put their cream on the market while working with the FDA and before it's approved, it would be the first of its kind and would open the floodgates for every other company in the sector to do the same. That would be great but it would cause chaos.
Here's your proof although some of you are so emotional about this stock you may still not agree. Massroot MSRT applied to the Nasdaq and were denied. Massroot is a company with just a downloadable app for people to get info on the best cannabis in their areas. Nasdaq denied it because they said it aided and abetted something that is Federally illegal. If they won't approve an app for that do you really think they will take on a company that's selling a drug that's Federally illegal? Some of you still won't be convinced but Nasdaq won't take them on if they sell the cream in the US.
[url][/url][tag]insert-text-here[/tag]http://www.marketwatch.com/story/nasdaq-rejects-cannabis-companys-listing-application-2016-05-24
Do you understand now that they cannot get on Nasdaq if any of their revenue comes from selling their cream in the US because it is Federally illegal and that revenue and PPS are not the only basic requirements?
[url][/url][tag]insert-text-here[/Re: Vinpat post# 77977
Post # of 78091
Incorrect. NASDAQ requirement is basically the revenue and PPS. If/when OWCP gets there ($$$ revenue) it will be on NASDAQ if they decided to go that route.
Quote:
They're not going to get on the Nasdaq if their cream comes from the plant
Seize Opportunity. Trade at E*TRADE.Advertisement
tag]
First of all, you said they weren't going to sell it in the US until I showed you their agreement with Medmar.
I repeat it because you keep missing my point and responding to me and because people are misleading others on this board that OWCP is going to be able to uplist while they plan is to sell the cream in the US.
GW is developing a synthetic drug called Epidiolex that is in late clinical trials. They developed another drug called Sativex that is being sold in other countries after it received their versions of FDA approval. Sativex did not receive FDA approval in the US and is not being marketed or sold in the US. They could manufacture it and sell it in the legal states in the US but it would be a violation of Federal law so they aren't.
You should probably do some research before you pipe in. FDA policy is that no drug that's manufactured from the plant will receive FDA approval. They consider it cannabis and illegal. Only synthetic cannabinoid drugs can obtain approval. It's no different than approved opiate pain meds that are all synthetic. The NYSE or Nasdaq will not take on a company that is solely developing natural cannabis drugs and they won't take on a company selling natural cannabis drugs or creams or dietary substances in the US.
Again, OWCP is looking to generate revenue from their cream which they can do in some states in the US and most of the rest of the world which could be very lucrative and they can use that to fund any long term plans they might have to develop synthetic drugs. But at this moment, OWCP is not in the same category as GW, Zynerba, Nemus, Insys or any other company developing synthetic cannabinoid drugs. Nothing wrong with that. OWCP should certainly have revenue before any of them.
Nasdaq or the NYSE will not list any company that break that has a product and/or policy that breaks US law. That's just common sense. If you don't believe it, find one cannabis company listed on either exchange. That doesn't mean companies that have synthetic drugs on the market or are developing synthetic cannabinoids to go through the FDA approval process. Why haven't any of the cannabis companies making money uplisted? Why are all these stocks still OTC and have difficulty raising money? Why hasn't GW sold Sativex in the legal US states? It's not just because they are start ups. Ask your broker if he/she thinks a company that technically violates Federal drug laws can be uplisted.
Medmar put $300k into OWCP for the rights to manufacture and sell the psoriasis cream in the states where medical marijuana is legal so there's no If about selling it here so read up. That means Nasdaq isn't happening. OWCP might generate great revenue from the cream but they are not yet in the same category as companies developing synthetic drugs like GW, Zynerba, Cara, Nemus and a few others. OWCP is developing drugs that derive from the plant fp now which is a totally different animal.
This is a revenue play right now that could make everyone very happy but their other drug candidates are a long way out to be approved in most countries because they are not synthetic.
OWCP states they plan on selling the cream only in states where medical cannabis is legal. That means the drug is not Federally legal which means that Nasdaq won't take them. It's really that simple. For people to speculate about an uplist at this point just gets hopes up. It may happen down the road but it isn't happening in the next few years. For now, this is a revenue play for a cream that could generate a lot of revenue.
Perhaps you should read OWCP's own website that states they have licensed Medmar to manufacture and distribute its products in the US. So unless you can show an officer of the company stating the opposite of what's posted on the website, their intent is to sell the cream in the US and therefore will not be able to uplist to the Nasdaq.
Then we agree if they sell the cream in the US they can't uplist to the Nasdaq. If they do sell it here, then we'll know. You should also know that if their drug candidates are derived from the plant and not synthetic then they won't receive FDA approval. No different than FDA approved pain meds. All of them are synthetic and anything derived from the poppy would not and has not received FDA approval.
You also need about $15 milion in cash besides the pps.
People have posted on this board that they've already secured a manufacturer and distributor in the US in the legal states. Read my previous posts asking that question and what the responses were. I'm not making it up. That's why I was saying they won't get on the Nasdaq if true.
If they sell the cream in the US it will violate Federal law. If GW sold Sativex in the US it would violate Federal law as well and that's why they don't sell it in the legal states. If OWCP sells their cream in the US it will violate Federal law. Do you understand that and why it would violate Federal law?
GWP never sold an illegal drug in the US. They could sell Sativex state by state but they know better. They'd be yanked immediately. And GWP was way further along 3 years ago. They had patents and had proven they could make their drugs synthetically which the FDA requires for approval.
You have to have a few years of revenue but again the cream is Federally illegal so Nasadaq won't touch it. You get that right?
Will a major chain like Walmart sell something that's not Federally legal? Can someone use a credit card to buy it if the Feds consider it illegal?
I'm not disagreeing with you at all. I'm just amazed they've been able to raise as much as they have considering what they have. In full disclosure, I've been thinking about pulling the trigger on this to own a couple of stocks in this sector that are relatively cheap. I already own Nemus but they are much further along and have 1/4 the outstanding shares so it's a much better play at this point. But just in case they can't execute, I've been looking at this one to have more coverage.
I didn't say they would never be a buyout candidate but they're not now. Number one their cream will not be Federally legal in the US. It can be manufactured and sold in states where it's legal but can't be imported or shipped across state lines. I don't even think it can be advertised as a psoriasis cream without FDA approval. The Feds would consider this cream the same as if it contained 3% heroin instead of THC as far as designation and approval goes.
Number 2, their other drug candidates might be valuable but if they are currently derived from the plant and not synthetic, the FDA won't approve it. Pharma is not going to step in until they show they can make their drug synthetically to FDA standards which takes at least 18 months and then they would need results from clinical trials. They're probably 3 years out for all that if they start today. All this talk about uplisting or buyouts is very premature. Uplisting is impossible if they sell the cream in the US that violates Federal law and and no cannabinoid company has been bought out yet that are years ahead of OWCP.
That's why I say that for now, this is a revenue play on the psoriasis cream that could do very well.
I don't think this is a scam company. I just think the timelines are about a year longer than what you think. In December, the CEO said they could be in clinicals in 18 months. However, they don't have secured patents yet and they have not started the process of being able to make their drug to FDA standards which takes at least a year. Add to that, once you make the drug you have to show it has a shelf life of 2 years. That takes 6 months because if it hasn't degraded in 6 months then they'll know it won't for 2 years based on known science.
As far as biosynthesis goes, it's hard to say if their process is better than what other companies are using that aren't doing chemical synthesis either. Some are using yeast instead of e-coli. For them to state that other companies are using the plant for their drugs just isn't true. The FDA has stated it will not approve a drug derived from the plant.
Bioinformatics is not a new concept. It's just what they're calling it.
I do think they have good management now and their ability to raise funds has been impressive considering how far along they are.
How is it possible? What would need to happen for them to uplist in the near future?
They're not going to get on the Nasdaq if their cream comes from the plant and isn't synthetic and their intent is to sell it in the US without FDA approval. Right now this is a cannabis company and is considered the same as if they were growing and selling. Cannabinoid companies are GW, Zyne, Axim, Nemus, CARA and a few others. They are companies with synthetic drugs and are going the FDA route. OWCP is not in the same category and is a revenue play on the cream. It's not a biotech play yet and no pharma company is going to acquire them with what they currently have.
Ability relatively speaking. They've raised more funds than I thought they'd be able to considering they have patents pending and have not made their drug candidates yet.